Experience with Sulperacef Used in the Treatment of Destructive Abdominal Diseases
Objective: to study the clinical efficacy of cefoperazone/sulbactam (Sulperacef, ABOLmed, Russia) in the treatment of acute surgical abdominal diseases.Subjects and methods. A study group included 31 patients with acute surgical abdominal diseases who took cefoperazone/sulbactam (sulperacef), 8 g/da...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Federal Research and Clinical Center of Intensive Care Medicine and Rehabilitology, Moscow, Russia
2007-12-01
|
| Series: | Общая реаниматология |
| Subjects: | |
| Online Access: | https://www.reanimatology.com/rmt/article/view/905 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850041114866745344 |
|---|---|
| author | Yu. A. Churlyaev P. G. Sitnikov S. V. Voyevodin N. S. Zuyeva |
| author_facet | Yu. A. Churlyaev P. G. Sitnikov S. V. Voyevodin N. S. Zuyeva |
| author_sort | Yu. A. Churlyaev |
| collection | DOAJ |
| description | Objective: to study the clinical efficacy of cefoperazone/sulbactam (Sulperacef, ABOLmed, Russia) in the treatment of acute surgical abdominal diseases.Subjects and methods. A study group included 31 patients with acute surgical abdominal diseases who took cefoperazone/sulbactam (sulperacef), 8 g/day, as an agent of empirical therapy. A control group comprised 42 patients treated in an intensive care unit (ICU) in 2005. This group received the traditional treatment regimen: cefotaxime (6—8 g/day) + amikacin (15 mg/kg/day) + metronidazole (1.5 g/day). The efficiency of antibiotic therapy was evaluated by the sepsis criteria (R. C. Bone): body temperature, leukocytes, heart rate, a need for respiratory support. In addition, the length of ICU stay, mortality, and a need for antibiotic switching were also taken into account.Results. The clinical effect of sulperacef was achieved in 22 out of the 31 patients given the agent. The duration of a course of sulperacef varied from 4 to 15 days (mean 7.7 days). On therapy day 5, the study group patients showed a reduction in the count of leukocytes from 12.15×109/l to 9.7×109/l whereas in the control group leukocytes were 13.43×109/l (p<0.05). The study group displayed a less significant temperature reaction on days 3 and 9 than in the controls (p<0.05). Tachycardia was less pronounced on day 3 (p<0.05).Conclusion. Cefoperazone/sulbactam (sulperacef) may be the drug of choice for starting empirical antibiotic therapy in patients with acute surgical abdominal diseases in ICU conditions. |
| format | Article |
| id | doaj-art-600d2d5ee78e4200828168876ab01c7a |
| institution | DOAJ |
| issn | 1813-9779 2411-7110 |
| language | English |
| publishDate | 2007-12-01 |
| publisher | Federal Research and Clinical Center of Intensive Care Medicine and Rehabilitology, Moscow, Russia |
| record_format | Article |
| series | Общая реаниматология |
| spelling | doaj-art-600d2d5ee78e4200828168876ab01c7a2025-08-20T02:55:52ZengFederal Research and Clinical Center of Intensive Care Medicine and Rehabilitology, Moscow, RussiaОбщая реаниматология1813-97792411-71102007-12-013616817110.15360/1813-9779-2007-6-168-171905Experience with Sulperacef Used in the Treatment of Destructive Abdominal DiseasesYu. A. Churlyaev0P. G. Sitnikov1S. V. Voyevodin2N. S. Zuyeva3Branch of the Research Institute of General Reanimatology, Russian Academy of Medical Sciences, NovokuznetskBranch of the Research Institute of General Reanimatology, Russian Academy of Medical Sciences, NovokuznetskBranch of the Research Institute of General Reanimatology, Russian Academy of Medical Sciences, NovokuznetskBranch of the Research Institute of General Reanimatology, Russian Academy of Medical Sciences, NovokuznetskObjective: to study the clinical efficacy of cefoperazone/sulbactam (Sulperacef, ABOLmed, Russia) in the treatment of acute surgical abdominal diseases.Subjects and methods. A study group included 31 patients with acute surgical abdominal diseases who took cefoperazone/sulbactam (sulperacef), 8 g/day, as an agent of empirical therapy. A control group comprised 42 patients treated in an intensive care unit (ICU) in 2005. This group received the traditional treatment regimen: cefotaxime (6—8 g/day) + amikacin (15 mg/kg/day) + metronidazole (1.5 g/day). The efficiency of antibiotic therapy was evaluated by the sepsis criteria (R. C. Bone): body temperature, leukocytes, heart rate, a need for respiratory support. In addition, the length of ICU stay, mortality, and a need for antibiotic switching were also taken into account.Results. The clinical effect of sulperacef was achieved in 22 out of the 31 patients given the agent. The duration of a course of sulperacef varied from 4 to 15 days (mean 7.7 days). On therapy day 5, the study group patients showed a reduction in the count of leukocytes from 12.15×109/l to 9.7×109/l whereas in the control group leukocytes were 13.43×109/l (p<0.05). The study group displayed a less significant temperature reaction on days 3 and 9 than in the controls (p<0.05). Tachycardia was less pronounced on day 3 (p<0.05).Conclusion. Cefoperazone/sulbactam (sulperacef) may be the drug of choice for starting empirical antibiotic therapy in patients with acute surgical abdominal diseases in ICU conditions.https://www.reanimatology.com/rmt/article/view/905peritonitisintensive careantibiotic resistancesulperacef |
| spellingShingle | Yu. A. Churlyaev P. G. Sitnikov S. V. Voyevodin N. S. Zuyeva Experience with Sulperacef Used in the Treatment of Destructive Abdominal Diseases Общая реаниматология peritonitis intensive care antibiotic resistance sulperacef |
| title | Experience with Sulperacef Used in the Treatment of Destructive Abdominal Diseases |
| title_full | Experience with Sulperacef Used in the Treatment of Destructive Abdominal Diseases |
| title_fullStr | Experience with Sulperacef Used in the Treatment of Destructive Abdominal Diseases |
| title_full_unstemmed | Experience with Sulperacef Used in the Treatment of Destructive Abdominal Diseases |
| title_short | Experience with Sulperacef Used in the Treatment of Destructive Abdominal Diseases |
| title_sort | experience with sulperacef used in the treatment of destructive abdominal diseases |
| topic | peritonitis intensive care antibiotic resistance sulperacef |
| url | https://www.reanimatology.com/rmt/article/view/905 |
| work_keys_str_mv | AT yuachurlyaev experiencewithsulperacefusedinthetreatmentofdestructiveabdominaldiseases AT pgsitnikov experiencewithsulperacefusedinthetreatmentofdestructiveabdominaldiseases AT svvoyevodin experiencewithsulperacefusedinthetreatmentofdestructiveabdominaldiseases AT nszuyeva experiencewithsulperacefusedinthetreatmentofdestructiveabdominaldiseases |